Clinical trialNCT00554463CompletedPhase 2Interventional

G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer

SponsorRadiation Therapy Oncology GroupEnrollment5Lung Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Drugs used in chemotherapy, such as cisplatin and etoposide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Colony-stimulating factors, such as G-CSF or pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help the immune system recover from the side effects of chemotherapy and radiation therapy. PURPOSE: This phase II trial is studying G-CSF and pegfilgrastim to see how well they work in treating neutropenia in patients undergoing combination chemotherapy and radiation therapy for limited stage small cell lung cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jeffrey Crawford, MD
Duke Cancer Institute
Study Chair
clinicaltrials.gov ↗
Michael A. Samuels, MD
CCOP - Mount Sinai Medical Center
Study Chair
clinicaltrials.gov ↗
Ritsuko U. Komaki, MD, FACR
M.D. Anderson Cancer Center
Study Chair
clinicaltrials.gov ↗
Rogerio C. Lilenbaum, MD
Mount Sinai Comprehensive Cancer Center at Mount Sinai Medical Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

University of Florida Shands Cancer Center
Gainesville, Florida, United States
Ccop - Mount Sinai Medical Center
Miami Beach, Florida, United States
Lucille P. Markey Cancer Center at University of Kentucky
Lexington, Kentucky, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Northern Rockies Radiation Oncology Center
Billings, Montana, United States
Methodist Estabrook Cancer Center
Omaha, Nebraska, United States
Mcdowell Cancer Center at Akron General Medical Center
Akron, Ohio, United States
Summa Center for Cancer Care at Akron City Hospital
Akron, Ohio, United States
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
Cancer Research Uk Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford
Salem, Ohio, United States
Cancer Treatment Center
Wooster, Ohio, United States
Mcglinn Family Regional Cancer Center at Reading Hospital and Medical Center
Reading, Pennsylvania, United States
Veterans Affairs Medical Center - Milwaukee
Milwaukee, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Cisplatin →Etoposide →Filgrastim →Pegfilgrastim →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2008
Primary completion: 31 Aug 2011
Completion: 3 Aug 2011
Last update posted: 29 May 2019
Registered enrollment: 5
Registry id: NCT00554463

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.